Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individuals

Raiees Andrabi, Constance Williams, Xiao Hong Wang, Liuzhe Li, Alok K. Choudhary, Naveet Wig, Ashutosh Biswas, Kalpana Luthra, Arthur Nadas, Michael S. Seaman, Phillipe Nyambi, Susan Zolla-Pazner, Miroslaw K. Gorny

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


One approach to the development of an HIV vaccine is to design a protein template which can present gp120 epitopes inducing cross-neutralizing antibodies. To select a V3 sequence for immunogen design, we compared the neutralizing activities of 18 anti-V3 monoclonal antibodies (mAbs) derived from Cameroonian and Indian individuals infected with clade AG and C, respectively. It was found that V3 mAbs from the Cameroonian patients were significantly more cross-neutralizing than those from India. Interestingly, superior neutralizing activity of Cameroonian mAbs was also observed among the nine VH5-51/VL lambda genes encoding V3 mAbs which mediate a similar mode of recognition. This correlated with higher relative binding affinity to a variety of gp120s and increased mutation rates in V3 mAbs from Cameroon. These results suggest that clade C V3 is probably weakly immunogenic and that the V3 sequence of CRF02_AG viruses can serve as a plausible template for vaccine immunogen design.

Original languageEnglish
Pages (from-to)81-88
Number of pages8
Issue number2
StatePublished - 10 May 2013
Externally publishedYes


  • HIV neutralizing antibodies
  • HIV-1
  • Human monoclonal antibodies
  • Immunoglobulin gene usage
  • Non-B clade HIV-1
  • V3 region


Dive into the research topics of 'Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individuals'. Together they form a unique fingerprint.

Cite this